{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:37:10Z","timestamp":1755797830348,"version":"3.44.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"DOI":"10.7759\/cureus.90425","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T22:18:27Z","timestamp":1755555507000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Brett","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soz","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasi","family":"Ponamala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sagaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riley","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Hematillake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandni","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-020-01542-3","article-title":"A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders","volume":"30","author":"Kim S","year":"2021","unstructured":"Kim S, Rush BS, Rice TR. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. Eur Child Adolesc Psychiatry. 2021, 30:1485-1501. 10.1007\/s00787-020-01542-3","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31796","article-title":"Psilocybin as a treatment for psychiatric illness: a meta-analysis","volume":"14","author":"Irizarry R","year":"2022","unstructured":"Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J. Psilocybin as a treatment for psychiatric illness: a meta-analysis. Cureus. 2022, 14:e31796. 10.7759\/cureus.31796","journal-title":"Cureus"},{"key":"ref3","article-title":"Ketamine-Assisted Psychotherapy: Clinical Outcomes and Self-Transcendence in Depression and Post-Traumatic Stress Disorder [dissertation]","author":"Montjoy JF","year":"2022","unstructured":"Montjoy JF. Ketamine-Assisted Psychotherapy: Clinical Outcomes and Self-Transcendence in Depression and Post-Traumatic Stress Disorder [dissertation]. University of Arizona, Tucson, AZ; 2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05121-6","article-title":"Ketamine's rapid and sustained antidepressant effects are driven by distinct mechanisms","volume":"81","author":"Rawat R","year":"2024","unstructured":"Rawat R, Tunc-Ozcan E, Dunlop S, et al.. Ketamine's rapid and sustained antidepressant effects are driven by distinct mechanisms. Cell Mol Life Sci. 2024, 81:105. 10.1007\/s00018-024-05121-6","journal-title":"Cell Mol Life Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27065","article-title":"Clinical uses of ketamine in children: a narrative review","volume":"14","author":"Bali A","year":"2022","unstructured":"Bali A, Dang AK, Gonzalez DA, Kumar R, Asif S. Clinical uses of ketamine in children: a narrative review. Cureus. 2022, 14:e27065. 10.7759\/cureus.27065","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00767","article-title":"Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies","volume":"9","author":"Li CT","year":"2018","unstructured":"Li CT, Yang KC, Lin WC. Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies. Front Psychiatry. 2018, 9:767. 10.3389\/fpsyt.2018.00767","journal-title":"Front Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2016.11.064","article-title":"Glutamate dysregulation and glutamatergic therapeutics for PTSD: evidence from human studies","volume":"649","author":"Averill LA","year":"2017","unstructured":"Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: evidence from human studies. Neurosci Lett. 2017, 649:147-155. 10.1016\/j.neulet.2016.11.064","journal-title":"Neurosci Lett"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/13.4.307","article-title":"What is the evidence for the safety and efficacy of using ketamine in children?","volume":"13","author":"Dolansky G","year":"2008","unstructured":"Dolansky G, Shah A, Mosdossy G, Rieder M. What is the evidence for the safety and efficacy of using ketamine in children?. Paediatr Child Health. 2008, 13:307-308. 10.1093\/pch\/13.4.307","journal-title":"Paediatr Child Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1192\/bja.2022.14","article-title":"Recent advances in the psychopharmacology of major depressive disorder","volume":"29","author":"Alexander L","year":"2023","unstructured":"Alexander L, Young AH. Recent advances in the psychopharmacology of major depressive disorder. BJPsych Adv. 2023, 29:117-130. 10.1192\/bja.2022.14","journal-title":"BJPsych Adv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-022-01363-y","article-title":"The emerging field of psychedelic psychotherapy","volume":"24","author":"Barber GS","year":"2022","unstructured":"Barber GS, Aaronson ST. The emerging field of psychedelic psychotherapy. Curr Psychiatry Rep. 2022, 24:583-590. 10.1007\/s11920-022-01363-y","journal-title":"Curr Psychiatry Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20010018","article-title":"Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial","volume":"178","author":"Dwyer JB","year":"2021","unstructured":"Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al.. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry. 2021, 178:352-362. 10.1176\/appi.ajp.2020.20010018","journal-title":"Am J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/pan.13752","article-title":"The effect of ketamine on emergence agitation in children: a systematic review and meta-analysis","volume":"29","author":"Ng KT","year":"2019","unstructured":"Ng KT, Sarode D, Lai YS, Teoh WY, Wang CY. The effect of ketamine on emergence agitation in children: a systematic review and meta-analysis. Paediatr Anaesth. 2019, 29:1163-1172. 10.1111\/pan.13752","journal-title":"Paediatr Anaesth"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al.. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021, 78:481-489. 10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson MW","year":"2017","unstructured":"Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017, 14:734-740. 10.1007\/s13311-017-0542-y","journal-title":"Neurotherapeutics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin GM","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al.. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022, 387:1637-1648. 10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-022-00265-5","article-title":"Psychedelics in the treatment of unipolar and bipolar depression","volume":"10","author":"Bosch OG","year":"2022","unstructured":"Bosch OG, Halm S, Seifritz E. Psychedelics in the treatment of unipolar and bipolar depression. Int J Bipolar Disord. 2022, 10:18. 10.1186\/s40345-022-00265-5","journal-title":"Int J Bipolar Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2021.62.528","article-title":"A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents","volume":"62","author":"Bogadi M","year":"2021","unstructured":"Bogadi M, Ka\u0161telan S. A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. Croat Med J. 2021, 62:528-530. 10.3325\/cmj.2021.62.528","journal-title":"Croat Med J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30214","article-title":"Potential therapeutic effects of psilocybin: a systematic review","volume":"14","author":"Goel DB","year":"2022","unstructured":"Goel DB, Zilate S. Potential therapeutic effects of psilocybin: a systematic review. Cureus. 2022, 14:e30214. 10.7759\/cureus.30214","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126713","article-title":"Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior","volume":"23","author":"Wojtas A","year":"2022","unstructured":"Wojtas A, Bysiek A, Wawrzczak-Bargiela A, et al.. Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior. Int J Mol Sci. 2022, 23:6713. 10.3390\/ijms23126713","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols DE","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016, 68:264-355. 10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.06.007","article-title":"Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions","volume":"29","author":"Millan MJ","year":"2008","unstructured":"Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. 2008, 29:454-464. 10.1016\/j.tips.2008.06.007","journal-title":"Trends Pharmacol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes NM","year":"1999","unstructured":"Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999, 38:1083-1152. 10.1016\/s0028-3908(99)00010-6","journal-title":"Neuropharmacology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.20552","article-title":"Activity patterns of serotonin neurons underlying cognitive flexibility","volume":"6","author":"Matias S","year":"2017","unstructured":"Matias S, Lottem E, Dugu\u00e9 GP, Mainen ZF. Activity patterns of serotonin neurons underlying cognitive flexibility. Elife. 2017, 6:10.7554\/eLife.20552","journal-title":"Elife"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2007.02384.x","article-title":"Investigating the pharmacodynamics of ketamine in children","volume":"18","author":"Herd DW","year":"2008","unstructured":"Herd DW, Anderson BJ, Keene NA, Holford NH. Investigating the pharmacodynamics of ketamine in children. Paediatr Anaesth. 2008, 18:36-42. 10.1111\/j.1460-9592.2007.02384.x","journal-title":"Paediatr Anaesth"},{"key":"ref26","article-title":"Comparison of cardiovascular and respiratory changes during induction, maintenance and recovery with sevoflurane and propofol in pediatric day care anesthesia","volume":"5","author":"Patel N","year":"2013","unstructured":"Patel N. Comparison of cardiovascular and respiratory changes during induction, maintenance and recovery with sevoflurane and propofol in pediatric day care anesthesia. J Chem Pharm Res. 2013, 5:562-565.","journal-title":"J Chem Pharm Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.924647","article-title":"The safety of propofol versus sevoflurane for general anesthesia in children: a meta-analysis of randomized controlled trials","volume":"9","author":"Zhao Y","year":"2022","unstructured":"Zhao Y, Qin F, Liu Y, Dai Y, Cen X. The safety of propofol versus sevoflurane for general anesthesia in children: a meta-analysis of randomized controlled trials. Front Surg. 2022, 9:924647. 10.3389\/fsurg.2022.924647","journal-title":"Front Surg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.36348\/sjmps.2023.v09i03.009","article-title":"Low dose propofol at the end of sevoflurane anesthesia reduces emergence agitation in children: a prospective observational study","volume":"9","author":"Ibrahim ME","year":"2023","unstructured":"Ibrahim ME, Nahar N, Ferdous A, Loban AH. Low dose propofol at the end of sevoflurane anesthesia reduces emergence agitation in children: a prospective observational study. Saudi J Med Pharm Sci. 2023, 9:197-202. 10.36348\/sjmps.2023.v09i03.009","journal-title":"Saudi J Med Pharm Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.23lr03607","article-title":"Is intravenous ketamine better than intranasal esketamine for treating treatment-resistant depression?","volume":"26","author":"Mansuri Z","year":"2024","unstructured":"Mansuri Z, Shah B, Yadav G, et al.. Is intravenous ketamine better than intranasal esketamine for treating treatment-resistant depression?. Prim Care Companion CNS Disord. 2024, 26:23lr03607. 10.4088\/PCC.23lr03607","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2023.05.031","article-title":"Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial","volume":"63","author":"Zhou Y","year":"2024","unstructured":"Zhou Y, Lan X, Wang C, et al.. Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2024, 63:507-518. 10.1016\/j.jaac.2023.05.031","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114911","article-title":"Ketamine use in pediatric depression: a systematic review","volume":"317","author":"Meshkat S","year":"2022","unstructured":"Meshkat S, Rosenblat JD, Ho RC, et al.. Ketamine use in pediatric depression: a systematic review. Psychiatry Res. 2022, 317:114911. 10.1016\/j.psychres.2022.114911","journal-title":"Psychiatry Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji A","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021, 278:542-555. 10.1016\/j.jad.2020.09.071","journal-title":"J Affect Disord"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo C","year":"2023","unstructured":"Loo C, Glozier N, Barton D, et al.. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry. 2023, 223:533-541. 10.1192\/bjp.2023.79","journal-title":"Br J Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0030","article-title":"Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study","volume":"28","author":"Cullen KR","year":"2018","unstructured":"Cullen KR, Amatya P, Roback MG, et al.. Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. J Child Adolesc Psychopharmacol. 2018, 28:437-444. 10.1089\/cap.2018.0030","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto T","year":"2016","unstructured":"Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016, 46:1459-1472. 10.1017\/S0033291716000064","journal-title":"Psychol Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.860882","article-title":"The mechanisms behind rapid antidepressant effects of ketamine: a systematic review with a focus on molecular neuroplasticity","volume":"13","author":"Kang MJ","year":"2022","unstructured":"Kang MJ, Hawken E, Vazquez GH. The mechanisms behind rapid antidepressant effects of ketamine: a systematic review with a focus on molecular neuroplasticity. Front Psychiatry. 2022, 13:860882. 10.3389\/fpsyt.2022.860882","journal-title":"Front Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: practical considerations for dosing and administration","volume":"13","author":"MacCallum CA","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022, 13:1040217. 10.3389\/fpsyt.2022.1040217","journal-title":"Front Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris RL","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017, 42:2105-2113. 10.1038\/npp.2017.84","journal-title":"Neuropsychopharmacology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris RL","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, et al.. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017, 7:13187. 10.1038\/s41598-017-13282-7","journal-title":"Sci Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011611.pub2","article-title":"Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults","author":"McCloud TL","year":"2015","unstructured":"McCloud TL, Caddy C, Jochim J, et al.. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015, CD011611. 10.1002\/14651858.CD011611.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.08.040","article-title":"Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder\/fear of harm phenotype","volume":"147","author":"Papolos DF","year":"2013","unstructured":"Papolos DF, Teicher MH, Faedda GL, Murphy P, Mattis S. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder\/fear of harm phenotype. J Affect Disord. 2013, 147:431-436. 10.1016\/j.jad.2012.08.040","journal-title":"J Affect Disord"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab023","article-title":"Ketamine for bipolar depression: a systematic review","volume":"24","author":"Bahji A","year":"2021","unstructured":"Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021, 24:535-541. 10.1093\/ijnp\/pyab023","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xhgg.2022.100138","article-title":"An open-label study evaluating the safety, behavioral, and electrophysiological outcomes of low-dose ketamine in children with ADNP syndrome","volume":"3","author":"Kolevzon A","year":"2022","unstructured":"Kolevzon A, Levy T, Barkley S, et al.. An open-label study evaluating the safety, behavioral, and electrophysiological outcomes of low-dose ketamine in children with ADNP syndrome. HGG Adv. 2022, 3:100138. 10.1016\/j.xhgg.2022.100138","journal-title":"HGG Adv"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue P","year":"2018","unstructured":"Glue P, Neehoff SM, Medlicott NJ, Gray A, Kibby G, McNaughton N. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018, 32:663-667. 10.1177\/0269881118762073","journal-title":"J Psychopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-024-02458-y","article-title":"Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review","volume":"34","author":"Bruton AM","year":"2025","unstructured":"Bruton AM, Wesemann DG, Machingo TA, Majak G, Johnstone JM, Marshall RD. Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry. 2025, 34:141-157. 10.1007\/s00787-024-02458-y","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/da.22875","article-title":"Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression","volume":"36","author":"Salloum NC","year":"2019","unstructured":"Salloum NC, Fava M, Freeman MP, et al.. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019, 36:235-243. 10.1002\/da.22875","journal-title":"Depress Anxiety"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1141988","article-title":"Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses","volume":"14","author":"Wolfson PE","year":"2023","unstructured":"Wolfson PE, Andries J, Ahlers D, Whippo M. Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses. Front Psychiatry. 2023, 14:1141988. 10.3389\/fpsyt.2023.1141988","journal-title":"Front Psychiatry"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231177240","article-title":"The safety of repeated ketamine dosing in paediatrics: a systematic review","volume":"37","author":"James L","year":"2023","unstructured":"James L, James IG, Wakefield J. The safety of repeated ketamine dosing in paediatrics: a systematic review. J Psychopharmacol. 2023, 37:757-763. 10.1177\/02698811231177240","journal-title":"J Psychopharmacol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/jts.23013","article-title":"A clinician's guide to the 2023 VA\/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder","volume":"37","author":"Lang AJ","year":"2024","unstructured":"Lang AJ, Hamblen JL, Holtzheimer P, et al.. A clinician's guide to the 2023 VA\/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. J Trauma Stress. 2024, 37:19-34. 10.1002\/jts.23013","journal-title":"J Trauma Stress"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder A","year":"2014","unstructured":"Feder A, Parides MK, Murrough JW, et al.. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014, 71:681-688. 10.1001\/jamapsychiatry.2014.62","journal-title":"JAMA Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder A","year":"2021","unstructured":"Feder A, Costi S, Rutter SB, et al.. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021, 178:193-202. 10.1176\/appi.ajp.2020.20050596","journal-title":"Am J Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01266-9","article-title":"Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial","volume":"47","author":"Abdallah CG","year":"2022","unstructured":"Abdallah CG, Roache JD, Gueorguieva R, et al.. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022, 47:1574-1581. 10.1038\/s41386-022-01266-9","journal-title":"Neuropsychopharmacology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2022.12.048","article-title":"Psychedelic-assisted therapies and pediatric palliative care: new tools for hope and healing (TH118A)","volume":"65","author":"Waldman E","year":"2023","unstructured":"Waldman E, Adrian C, Spence D. Psychedelic-assisted therapies and pediatric palliative care: new tools for hope and healing (TH118A). J Pain Symptom Manage. 2023, 65:e261-e262. 10.1016\/j.jpainsymman.2022.12.048","journal-title":"J Pain Symptom Manage"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2023.0007","article-title":"Past is prologue: ethical issues in pediatric psychedelics research and treatment","volume":"66","author":"Edelsohn GA","year":"2023","unstructured":"Edelsohn GA, Sisti D. Past is prologue: ethical issues in pediatric psychedelics research and treatment. Perspect Biol Med. 2023, 66:129-144. 10.1353\/pbm.2023.0007","journal-title":"Perspect Biol Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker JJ","year":"2018","unstructured":"Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018, 142:200-218. 10.1016\/j.neuropharm.2017.12.040","journal-title":"Neuropharmacology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi M","year":"2022","unstructured":"Yavi M, Lee H, Henter ID, Park LT, Zarate CA Jr. Ketamine treatment for depression: a review. Discov Ment Health. 2022, 2:9. 10.1007\/s44192-022-00012-3","journal-title":"Discov Ment Health"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.927984","article-title":"Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders","volume":"13","author":"Vorobyeva N","year":"2022","unstructured":"Vorobyeva N, Kozlova AA. Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders. Front Pharmacol. 2022, 13:927984. 10.3389\/fphar.2022.927984","journal-title":"Front Pharmacol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.7202\/1089784ar","article-title":"Should adolescents be included in emerging psychedelic research?","volume":"5","author":"Rajwani K","year":"2022","unstructured":"Rajwani K. Should adolescents be included in emerging psychedelic research?. Can J Bioeth Rev. 2022, 5:36-43. 10.7202\/1089784ar","journal-title":"Can J Bioeth Rev"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0078","article-title":"Parental attitudes toward use of ketamine in adolescent mood disorders and suicidality","volume":"31","author":"Mathai DS","year":"2021","unstructured":"Mathai DS, McCathern AG, Guzick AG, et al.. Parental attitudes toward use of ketamine in adolescent mood disorders and suicidality. J Child Adolesc Psychopharmacol. 2021, 31:553-561. 10.1089\/cap.2021.0078","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks PS","year":"2015","unstructured":"Hendricks PS, Johnson MW, Griffiths RR. Psilocybin, psychological distress, and suicidality. J Psychopharmacol. 2015, 29:1041-1043. 10.1177\/0269881115598338","journal-title":"J Psychopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/364525-exploring-the-therapeutic-potential-of-ketamine-and-psilocybin-in-comparison-to-current-treatment-regimens-for-treatment-resistant-depression-mood-disorders-and-post-traumatic-stress-disorder-in-the-pediatric-population-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T22:18:28Z","timestamp":1755555508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/364525-exploring-the-therapeutic-potential-of-ketamine-and-psilocybin-in-comparison-to-current-treatment-regimens-for-treatment-resistant-depression-mood-disorders-and-post-traumatic-stress-disorder-in-the-pediatric-population-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.90425","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}